Ashwin Chetty
he/him/his
About
Research
Publications
Featured Publications
Proportion of Obesity-Related Conditions Attributable to Obesity and Overweight in US Youth
Chetty A, Chen A, Hajduk A, Sharifi M, Nugent J. Proportion of Obesity-Related Conditions Attributable to Obesity and Overweight in US Youth. JAMA Pediatrics 2025, 179 PMID: 40853652, PMCID: PMC12379120, DOI: 10.1001/jamapediatrics.2025.2716.Peer-Reviewed Original ResearchGlucagon-Like Peptide-1 Receptor Agonist Eligibility Among US Adolescents and Young Adults
Chetty A, Sharifi M, Nugent J. Glucagon-Like Peptide-1 Receptor Agonist Eligibility Among US Adolescents and Young Adults. JAMA Pediatrics 2025, 179 PMID: 40758363, PMCID: PMC12322816, DOI: 10.1001/jamapediatrics.2025.2308.Peer-Reviewed Original ResearchOnline Advertising of Compounded Glucagon-Like Peptide-1 Receptor Agonists
Chetty A, Chillakanti M, Ramachandran R, Ross J, Chen A. Online Advertising of Compounded Glucagon-Like Peptide-1 Receptor Agonists. JAMA Health Forum 2025, 6: e245018. PMID: 39820389, PMCID: PMC11742527, DOI: 10.1001/jamahealthforum.2024.5018.Peer-Reviewed Original ResearchClinical Characteristics of Adults at Risk of Medicaid Disenrollment Due to HR 1 Work Requirements.
Chetty AK, Ross JS, Chen AS. Clinical Characteristics of Adults at Risk of Medicaid Disenrollment Due to HR 1 Work Requirements. JAMA 2025 PMID: 41032309, DOI: 10.1001/jama.2025.16533.Peer-Reviewed Original ResearchPrevalence of Excess Adiposity by Body Mass Index Category Among US Children and Adolescents.
Chetty AK, Nugent JT, Fenick AM, Sharifi M. Prevalence of Excess Adiposity by Body Mass Index Category Among US Children and Adolescents. JAMA Pediatr 2025 PMID: 41182761, DOI: 10.1001/jamapediatrics.2025.4291.Peer-Reviewed Original Research
2025
Compounded GLP-1 Receptor Agonists: Opportunity for Compassionate Conversation
Chetty A, Chen A. Compounded GLP-1 Receptor Agonists: Opportunity for Compassionate Conversation. Journal Of General Internal Medicine 2025, 1-2. PMID: 40696223, DOI: 10.1007/s11606-025-09765-3.Commentaries, Editorials and LettersImpact of Preoperative LDL Level on Lower Extremity Revascularization Outcomes
Carter W, Alappan U, Chetty A, Wells N, Alameddine D, Slade M, Possick S, Ochoa Chaar C. Impact of Preoperative LDL Level on Lower Extremity Revascularization Outcomes. Annals Of Vascular Surgery 2025, 122: 239-247. PMID: 40651525, DOI: 10.1016/j.avsg.2025.07.016.Peer-Reviewed Original ResearchLower extremity revascularizationPeripheral arterial diseaseRetrospective chart reviewProportion of patientsRetrospective chart review of patientsChart review of patientsLDL testingReview of patientsCox regression analysisAdverse cardiovascular eventsChronic limb-threatening ischemiaHybrid lower extremity revascularizationBurden of comorbiditiesAssociated with outcomeLimb-threatening ischemiaOld white maleBaseline LDLTertiary centerStatin useLipid testingCardiovascular eventsFollow-upLDL levelsLower LDLRevascularization outcomesPrevalence of Heart Failure With Type 1 Diabetes and Type 2 Diabetes Among US Adults
Chetty A, Chen A. Prevalence of Heart Failure With Type 1 Diabetes and Type 2 Diabetes Among US Adults. Endocrine Practice 2025, 31: 1087-1088. PMID: 40316141, DOI: 10.1016/j.eprac.2025.04.019.Peer-Reviewed Original Research
2024
Analysis of Online Crowdfunding Among Patients Pursuing Metabolic and Bariatric Surgery in the United States
Hamid S, Graetz E, Bakkila B, Chao G, Zolfaghari E, Schultz K, Chetty A, Trabilsy M, Schneider E, Gibbs K. Analysis of Online Crowdfunding Among Patients Pursuing Metabolic and Bariatric Surgery in the United States. Obesity Surgery 2024, 35: 170-180. PMID: 39633092, DOI: 10.1007/s11695-024-07605-7.Peer-Reviewed Original ResearchBariatric surgeryNon-medical expensesRoux-en-Y gastric bypassNon-surgical attemptsRoux-en-YObesity-associated diseasesSleeve gastrectomyGastric bypassBiliopancreatic diversionDuodenal switchAssessed associationsLogistic regressionSurgeryIQRPatientsMedianDiseaseLost wagesHealth-related diseasesUnmet financial needsEligibility for Anti-Obesity Medications Among Medicare Beneficiaries with Overweight or Obesity
Chetty A, Khunte M, Chen A, Jastreboff A, Krumholz H, Lu Y. Eligibility for Anti-Obesity Medications Among Medicare Beneficiaries with Overweight or Obesity. Journal Of General Internal Medicine 2024, 40: 1467-1469. PMID: 39477867, PMCID: PMC12045892, DOI: 10.1007/s11606-024-09178-8.Peer-Reviewed Original Research
News
News
- November 11, 2025
New Study Reveals High Disease Burden Among At-Risk Medicaid Beneficiaries
- November 03, 2025
Evaluating the Clinical Necessity of Obtaining Additional Measurements in Children with High BMI
- October 03, 2025Source: HCPLive
New Research Letter Reveals GLP-1 Access Deficits for Adolescents and Young Adults
- August 25, 2025
Examining the Impact of Treating and Preventing Obesity to Prevent Obesity-Related Conditions